Xenical (orlistat) guide

Orlistat reduces absorption of some dietary fat. It does not suppress appetite, and it does not work without the agreed nutrition plan alongside it — the capsule only does its job at meals that actually contain fat.

​

How it works

Orlistat (tetrahydrolipstatin) is a potent, selective inhibitor of gastric and pancreatic lipases. It acts within the lumen of the stomach and small intestine, forming a covalent bond with the serine-152 residue of the lipase active site. This inactivates the enzyme, preventing hydrolysis of dietary triglycerides into absorbable free fatty acids and monoglycerides. The undigested triglycerides pass through the gut unabsorbed, creating a caloric deficit. At the recommended therapeutic dose of 120 mg three times daily, orlistat inhibits approximately 30% of dietary fat absorption. Systemic absorption is minimal — plasma concentrations of intact orlistat are below 5 ng/mL after an oral dose. (PMID 9225172; DailyMed orlistat label)

​

Clinical evidence

The XENDOS trial (XENical in the Prevention of Diabetes in Obese Subjects) was a 4-year, double-blind, randomised study in 3,305 patients with obesity (BMI ≥30 kg/m²) who received lifestyle modification plus either orlistat 120 mg or placebo three times daily. Coprimary endpoints were time to onset of type 2 diabetes and change in body weight. After 4 years, orlistat-treated patients lost a mean of 5.8 kg versus 3.0 kg with placebo (p < 0.001). The cumulative incidence of type 2 diabetes was 6.2% with orlistat and 9.0% with placebo, corresponding to a 37.3% relative risk reduction (p = 0.0032). The preventive effect was confined to the subgroup with impaired glucose tolerance at baseline. Completion rates at 4 years were 52% in the orlistat group and 54% in the placebo group; the primary analysis used intention to treat with last observation carried forward. (PMID 14693982)

​

Contraindications explained

Orlistat is contraindicated in chronic malabsorption syndrome because it amplifies the underlying inability to absorb nutrients — the medicine’s mechanism (lipase inhibition) worsens fat malabsorption. It is also contraindicated in cholestasis, since bile salts are required for the emulsification of dietary fat that precedes lipase action; without adequate bile flow, orlistat cannot reach its site of action effectively and fat-soluble vitamin deficiency is more likely.

​

Population considerations

Because orlistat acts within the gut lumen and systemic absorption is minimal (plasma concentrations below 5 ng/mL), no dose adjustment is required in hepatic or renal impairment. Nonetheless, fat-soluble vitamin status should be monitored in patients with pre-existing deficiency risk. Orlistat is not recommended during pregnancy — weight-loss treatment is not appropriate in pregnancy, and the potential for fat-soluble vitamin malabsorption adds risk. (DailyMed orlistat label; EMA Xenical product information)

​

How to use

Two rules work together at every meal — when the capsule is taken, and what the meal contains.

​

Dose schedule

Use no more than one 120 mg capsule per qualifying main meal. If a multivitamin containing vitamins A, D, E and K is recommended, separate it from orlistat by at least two hours — often at bedtime. At a twelve-week review, the prescriber checks weight change, side effects, adherence, nutrition, and interacting medicines. EU product information advises stopping if the expected response threshold has not been reached.

​

What has been reported

These bowel effects often improve when dietary fat is distributed and reduced.

​

Contact your doctor if

• Severe or persistent abdominal pain, vomiting, yellow skin or eyes, dark urine, or a severe allergic reaction
• Rectal bleeding, severe diarrhoea, symptoms of kidney stones, or bowel effects that are difficult to manage
• You start an anticoagulant, ciclosporin, levothyroxine, an epilepsy medicine, or another medicine with an absorption concern

​

Storage

Keep in the original package, away from moisture and direct heat, and out of children’s reach. Follow the temperature limit on your pack and do not use it after the expiry date.

​

What to expect

Progress is reviewed after 12 weeks and at intervals thereafter. Results vary, and continuation depends on response, tolerance, and clinical suitability.

​

Common questions

​

How Hi-Doctor handles it

A licensed EU doctor reviews your case and, if appropriate, issues a prescription alongside the agreed nutrition plan. Orlistat is one of the options a doctor may consider — see the full set on the orforglipron page, which lists every EU-authorised weight-management medicine Hi-Doctor’s doctors work from. See also how a consultation works, the treatment areas Hi-Doctor covers, and how eligibility is decided in safety.

​

Start a consultation